A comprehensive view of Phase 2 Trial. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Sage Therapeutics announces topline results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the treatment of mild cognitive impairment in Parkinson’s disease
Published: April 17, 2024 by Sage Therapeutics
Sanofi's frexalimab shows high efficacy in 48-week Phase 2 trial for multiple sclerosis, with an annualized relapse rate of 0.04 for high-dose variants; Phase 3 studies have begun for both relapsing and non-relapsing secondary progressive MS
Published: April 17, 2024 by Sanofi SA
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
Published: April 07, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Moderna reports its investigational injectable mRNA therapy mRNA-3927 shows potential clinical benefits and infrequent side effects in phase 1/2 study; therapy is aimed at treating inherited metabolic disorder propionic acidemia
Published: April 03, 2024 by Moderna Inc.
Novo Nordisk acquires Cardior Pharmaceuticals for up to €1.025B, aiming to strengthen its portfolio in cardiovascular disease treatments; deal includes Cardior's RNA-targeting therapies and its Phase 2 lead compound CDR132L for heart failure
Published: March 25, 2024 by GlobeNewswire Europe

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count